The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1359-1364

  Shinagawa, Akiko ^a   Yoshida, Yoshio ^a   Kurokawa, Tetsuji ^a   Horiuchi, Yuko ^a   Tsuyoshi, Hideaki ^a   Orisaka, Makoto ^a   Sawamura, Yoko ^a   Kleinman, Hynda K ^b   Kotsuji, Fumikazu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Anti angiogenic peptide C16Y; Bcl 2 Bax ratio; Cisplatin; Synergy

Indexed keywords

ANGIOGENESIS INHIBITOR; C16Y; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NIH 3T3 CELLS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 80054809742     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1134     Document Type: Article

References (17)

1. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003. (Pubitemid 37487159)
2. Pupa SM, Menard S, Forti S and Tagliabue E: New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192: 259-267, 2002. (Pubitemid 34827603)
3. Powell SK and Kleinman HK: Neuronal laminins and their cellular receptors. Int J Biochem Cell Biol 29: 401-414, 1997. (Pubitemid 27230994)
4. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y and Martin GR: YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238: 1132-1134, 1987. (Pubitemid 18011956)
5. Ponce ML, Hibino S, Lebioda AM, Mochizuki M, Nomizu M and Kleinman HK: Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res 63: 5060-5064, 2003. (Pubitemid 37022645)
6. Martin L and Schilder R: Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 25: 2894-2901, 2007. (Pubitemid 47123153)
7. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
8. Aharoni D, Meiri I, Atzmon R, Vlodavsky I and Amsterdam A: Differential effect of components of the extracellular matrix on differentiation and apoptosis. Curr Biol 7: 43-51, 1997. (Pubitemid 27058939)
9. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
10. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002. (Pubitemid 37328796)
11. Trikha M, Zhou Z, Timar J, Raso E, Kennel M and Emmell E: Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 6: 2824-2833, 2002. (Pubitemid 34525767)
12. Varner JA, Brooks PC and Cheresh DA: Review: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 3: 367-374, 1995.
13. waf1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433, 1996.
14. Li J, Tan H, Dong X, Xu Z, Shi C, Han X, Jiang H, Krissansen GW and Sun X: Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig Liver Dis 39: 557-565, 2007. (Pubitemid 46746642)
15. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S and Davis PJ: Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J 20: 1742-1744, 2006.
16. Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, Risberg B and Kopolovic J: AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90: 248-257, 2003. (Pubitemid 36952011)
17. Guo HY, Han JS, Zhang LF, Wang LN, Geng L and Chen GA: Immunohistochemical expression of integrin alphav, beta5 and beta3 in ovarian epithelial carcinoma: correlation with drug resistance of chemotherapy. Zhonghua Fu Chan Ke Za Zhi 39: 750-753, 2004 (In Chinese).